WO2002065834A8 - Novel formulations of carvedilol - Google Patents

Novel formulations of carvedilol

Info

Publication number
WO2002065834A8
WO2002065834A8 PCT/US2001/050872 US0150872W WO02065834A8 WO 2002065834 A8 WO2002065834 A8 WO 2002065834A8 US 0150872 W US0150872 W US 0150872W WO 02065834 A8 WO02065834 A8 WO 02065834A8
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
novel formulations
formulations
novel
angina
Prior art date
Application number
PCT/US2001/050872
Other languages
French (fr)
Other versions
WO2002065834A3 (en
WO2002065834A2 (en
Inventor
Vlassios Andronis
Kimberly A Lamey
Choon K Oh
Original Assignee
Smithkline Beecham Corp
Vlassios Andronis
Kimberly A Lamey
Choon K Oh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Vlassios Andronis, Kimberly A Lamey, Choon K Oh filed Critical Smithkline Beecham Corp
Priority to EP01273804A priority Critical patent/EP1335707A4/en
Priority to AU2001297631A priority patent/AU2001297631A1/en
Priority to US10/415,671 priority patent/US20040019096A1/en
Priority to JP2002565411A priority patent/JP2004518734A/en
Priority to CA002426811A priority patent/CA2426811A1/en
Publication of WO2002065834A2 publication Critical patent/WO2002065834A2/en
Publication of WO2002065834A3 publication Critical patent/WO2002065834A3/en
Publication of WO2002065834A8 publication Critical patent/WO2002065834A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to a novel formulations comprising carvedilol and methods of using these formulations to treat hypertension, congestive heart failure and angina.
PCT/US2001/050872 2000-10-24 2001-10-23 Novel formulations of carvedilol WO2002065834A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01273804A EP1335707A4 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol
AU2001297631A AU2001297631A1 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol
US10/415,671 US20040019096A1 (en) 2001-10-23 2001-10-23 Novel formulations of carvedilol
JP2002565411A JP2004518734A (en) 2000-10-24 2001-10-23 A new formulation of carvedilol
CA002426811A CA2426811A1 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24291100P 2000-10-24 2000-10-24
US60/242,911 2000-10-24

Publications (3)

Publication Number Publication Date
WO2002065834A2 WO2002065834A2 (en) 2002-08-29
WO2002065834A3 WO2002065834A3 (en) 2002-10-03
WO2002065834A8 true WO2002065834A8 (en) 2003-06-26

Family

ID=22916614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050872 WO2002065834A2 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol

Country Status (5)

Country Link
EP (1) EP1335707A4 (en)
JP (1) JP2004518734A (en)
AU (1) AU2001297631A1 (en)
CA (1) CA2426811A1 (en)
WO (1) WO2002065834A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3024399A (en) 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
IN191028B (en) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US20050019399A1 (en) * 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
EP1974726B1 (en) 2003-03-26 2010-01-13 Egalet A/S Matrix compositions for controlled delivery of drug substances
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512350A (en) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol composition treatment and delivery methods
JP5042041B2 (en) 2005-02-25 2012-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating and preventing cardiomyopathy and heart disease
HU227490B1 (en) * 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
AU2007281531B2 (en) 2006-08-01 2013-07-04 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
HU227881B1 (en) * 2007-02-23 2012-05-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
WO2008124088A2 (en) 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
FR2936709B1 (en) * 2008-10-02 2012-05-11 Ethypharm Sa ALCOHOL-RESISTANT TABLETS.
TWI415604B (en) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd Controlled release carvediolol formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19637082A1 (en) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
HUP0000759A3 (en) * 1997-03-11 2000-11-28 Darwin Discovery Ltd Cambridge Dosage forms comprising separate portions of r- and s-enantiomers
DE19816036A1 (en) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol
KR100336090B1 (en) * 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
DE19833119A1 (en) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Storage-stable injectable solution of vasodilator and beta blocker Carvedilol contains buffer, organic solvent, antioxidant and complexing agent
PE20001302A1 (en) * 1998-11-27 2000-11-30 Hoffmann La Roche PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE
CA2392085A1 (en) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
JP2003528914A (en) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー Concentrated solution of carvedilol

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release

Also Published As

Publication number Publication date
EP1335707A4 (en) 2005-07-06
AU2001297631A1 (en) 2002-09-04
CA2426811A1 (en) 2002-08-29
EP1335707A2 (en) 2003-08-20
JP2004518734A (en) 2004-06-24
WO2002065834A3 (en) 2002-10-03
AU2001297631A8 (en) 2005-09-15
WO2002065834A2 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2002065834A3 (en) Novel formulations of carvedilol
TNSN03083A1 (en) Mercaptoacetylamide derivatives, a process for their preparation and their use
WO2005051322A3 (en) Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
AU2002311012A1 (en) Endo-beta-1,4-glucanase from bacillus
EP1283235A3 (en) Composition, method of making, and method of using adhesive composition
NO20040158L (en) Method of amplifying a Chordopox virus.
WO2003000893A3 (en) Nucleic acids encoding g protein-coupled receptors
WO2003028645A3 (en) Novel compositions of carvedilol
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
AU2002303529A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
WO2002017858A3 (en) Role of fosb in bone formation
WO2001029032A8 (en) Process for the preparation of paroxetine
WO2003092625A3 (en) Carvedilol formulations
WO2003092626A3 (en) Carvedilol pharmasolve solvate
AU2002351560A1 (en) Treatment of congestive heart failure
WO2003005970A3 (en) Carvedilol polymorph
NO20034412D0 (en) Mercaptoacetylamide derivatives, process for their preparation and use
AU2003214299A1 (en) Hiv-1 virus tat-protein mutants
AU3757200A (en) Treatment of pulmonary hypertension
AU2002216911A1 (en) Method for the production of 4-(17alpha substituted 3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1E or 1Z)-oximes
WO2003039474A3 (en) Method and composition for the modulation of angiogenesis
AU2002245505A1 (en) Non-racemic hexafluoreleucine, and methods of making and using it
AUPR438501A0 (en) Method of modifying hardwood traits
AUPQ680900A0 (en) Method of modifying hardwood traits

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2426811

Country of ref document: CA

Ref document number: 10415671

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002565411

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001273804

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2002 UNDER (22) REPLACE "19 OCTOBER 2001 (19.10.2001)" BY "23 OCTOBER 2001 (23.10.2001)

WWP Wipo information: published in national office

Ref document number: 2001273804

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001273804

Country of ref document: EP